Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | < 10 mg kg-1 | In vivo effective dose of the compound was evaluated against Plasmodium berghei N by subcutaneous administration in mice | ChEMBL. | 14998331 |
ED50 (functional) | < 10 mg kg-1 | In vivo effective dose evaluated against Plasmodium berghei N by per oral administration in mice | ChEMBL. | 14998331 |
ED90 (functional) | < 10 mg kg-1 | In vivo effective dose evaluated against Plasmodium berghei N by subcutaneous administration in mice | ChEMBL. | 14998331 |
ED90 (functional) | < 10 mg kg-1 | In vivo effective dose of the compound was evaluated against Plasmodium berghei N by per oral administration in mice | ChEMBL. | 14998331 |
IC50 (functional) | = 3.1 nM | In vitro inhibitory concentration on chloroquine resistant Plasmodium falciparum FcB1 strain | ChEMBL. | 14998331 |
Parasitemia (functional) | = 18 % | In vivo antimalarial activity against Plasmodium bergi NK 173 in mice by intraperitoneal route at a concentration of 35.5 microM/kg at day 4 | ChEMBL. | 14998331 |
Parasitemia (functional) | = 45 % | In vivo antimalarial activity of the compound against Plasmodium bergi NK 173 in mice by intraperitoneal route at a concentration of 35.5 microM/kg at day 12 | ChEMBL. | 14998331 |
Reduction (functional) | = 93.3 % | Compound was evaluated for percentage reduction of parasitaemia at day 4 at a concentration of 10 mg/kg by per oral administration | ChEMBL. | 14998331 |
Reduction (functional) | = 98.1 % | Percentage reduction of parasitaemia at day 4 at a concentration of 10 mg/kg by subcutaneous administration | ChEMBL. | 14998331 |
Survival (functional) | = 4 % | Percent survival of mice after 20 days post infection of malarial parasite in out of 5 mice | ChEMBL. | 14998331 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 14998331 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.